SCHEMBL15613535

SCHEMBL15613535

Cn1cncc1COc1cc(F)cc(Oc2ccc(-c3nn(CC(C)(C)O)c4ncnc(N)c34)cc2)c1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ BTK Q06187 9/20 0.44
▸ PRKD3 O94806 1/20 0.44
▸ CYP1A2 P05177 2/20 0.44
▸ MAPK1 P28482 2/20 0.44
▸ KDM4E B2RXH2 2/20 0.44
▸ TP53 P04637 1/20 0.44
▸ CYP3A4 P08684 1/20 0.44
▸ MEN1 O00255 1/20 0.43
▸ KMT2A Q03164 1/20 0.43
▸ TDP1 Q9NUW8 1/20 0.43
▸ NUDT14 O95848 1/20 0.42
▸ NUDT5 Q9UKK9 1/20 0.42
▸ PIK3CD O00329 2/20 0.42
▸ PIK3CA P42336 1/20 0.42
▸ PIK3CB P42338 1/20 0.42
▸ PIK3CG P48736 1/20 0.42
▸ PRKDC P78527 1/20 0.42
▸ EGFR P00533 2/20 0.41
▸ LCK P06239 2/20 0.41
▸ JAK3 P52333 2/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15613525 0.90 SRC (0.48) BTKMAPK1NUDT14NUDT5PIK3CD
SCHEMBL16886178 0.89 BTK (0.47) BTKPRKD3CYP1A2MAPK1KDM4E
SCHEMBL15613642 0.89 BTK (0.45) BTKNUDT14NUDT5PIK3CDPIK3CA
SCHEMBL15613656 0.88 CYP1A2 (0.46) BTKPRKD3CYP1A2MAPK1KDM4E
SCHEMBL16886190 0.88 CYP1A2 (0.47) BTKPRKD3CYP1A2MAPK1KDM4E
SCHEMBL15613564 0.86 BTK (0.49) BTKPRKD3CYP1A2MAPK1KDM4E
SCHEMBL15613537 0.85 CYP1A2 (0.47) BTKPRKD3CYP1A2MAPK1KDM4E
SCHEMBL15613688 0.84 SRC (0.54) PIK3CDPIK3CAPIK3CBPIK3CGPRKDC
SCHEMBL15613501 0.83 MAPK1 (0.46) BTKPRKD3CYP1A2MAPK1KDM4E
SCHEMBL16886189 0.83 MAPK1 (0.47) BTKPRKD3CYP1A2MAPK1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9796716-B2 Selective inhibitors of Tec and Src protein kinase families PHARMASCIENCE, INC. (CA) 2017-10-24 — — US disclosed
US-9796716-B2 Selective inhibitors of Tec and Src protein kinase families PHARMASCIENCE, INC. (CA) 2017-10-24 — — US disclosed
US-20150191473-A1 PROTEIN KINASE INHIBITORS PHARMASCIENCE, INC. (CA) 2015-07-09 — — US disclosed
US-20150191473-A1 PROTEIN KINASE INHIBITORS PHARMASCIENCE, INC. (CA) 2015-07-09 — — US disclosed
WO-2013177668-A1 PROTEIN KINASE INHIBITORS PHARMASCIENCE, INC. (CA) 2013-12-05 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150191473-A1 PROTEIN KINASE INHIBITORS TEC, SRC, LCK BTK 10/4885PRKD3 179/4885CYP1A2 4734/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback